Dexmedetomidine may decrease the bupivacaine toxicity to heart.

OBJECTIVE

The purpose of our study was to explore the effect of dexmedetomidine on cardiac tolerance to bupivacaine.

METHOD

Human coronary endothelial cells were used to establish model. They were randomly divided into control (Con) group, dexmedetomidine (Dex) group, bupivacaine (Bupi) group, dexmedetomidine + bupivacaine group (DB group), and dexmedetomidine + bupivacaine + PI3K inhibitor (DB-inhibitor) group. Cell activity was measured by Cell counting kit-8 (CCK-8). Transwell was used to detect cell permeability. Western blotting was used to detect the protein expression of related factors.

RESULTS

There were no notable differences in cell activity among the five groups ( > 0.05). Dexmedetomidine significantly reduced the permeability of endothelial cells to bupivacaine and increased the protein expression of Zonulaoeeludens-1 (ZO-1) ( < 0.01). However, the aforementioned effects of dexmedetomidine were disappeared after the addition of PI3K inhibitors. Furthermore, Dex and DB markedly increased the protein expression of PI3K, p-Akt, and p-PTEN in comparison with Con group ( < 0.001), but there was no significant difference in p-PTEN among DB-inhibitor, Con, and Bupi groups ( > 0.05).

CONCLUSION

Dex reduced Bupi-induced vasopermeability through protein expression of ZO-1 and PI3K/Akt pathway, which may lead to the decrease of Bupi-induced cardiotoxicity.